Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takeda Pharmaceutical Co's revenue for the
three
months ended in Jun. 2026 was $7,588 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $29,655 Mil.
Takeda Pharmaceutical Co's Revenue per Share for the
three
months ended in Jun. 2026 was $4.73.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $18.55.
Warning Sign:
Takeda Pharmaceutical Co Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Takeda Pharmaceutical Co was 3.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 7.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Takeda Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 11.60% per year. The lowest was -3.30% per year. And the median was 4.05% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Revenue distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $29,655 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co (TKPHF) has a Revenue of $29,655 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Revenue too high?
Takeda Pharmaceutical Co's current Revenue is $29,655 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Revenue compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Revenue of $29,655 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Revenue is $29,655 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TKPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $29.62, compared to a current price of $35.89 — trading 21.2% above its estimated fair value. The current Revenue is $29,655 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TKPHF), the current Revenue is $29,655 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TKPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of $35.89 is trading 21.2% above its estimated GF Value™ of $29.62.
GuruFocus considers Takeda Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for TKPHF:
Revenue: $29,655 Mil
GF Value™: $29.62 vs. price of $35.89 (21.2% above fair value)
No single metric tells the full story. See the TKPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
77GF Score
Get the complete analysis for TKPHF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKPHF has been successfully added to your 
